VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand.

Slides:

Advertisements

Similar presentations

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.

Advertisements

Regulatory Considerations for the Safety Assessment of Live Biotherapeutic Products in Clinical Trials Cara Fiore, Ph D US Food and Drug Administration.

An Approach to Demonstration of Effectiveness

Licensing Pandemic Vaccines Novartis Vaccines Penny Heaton, MD, Global head clinical development clusters VRBPAC Washington DC, February 2012.

Pox-Protein Public-Private Partnership (P5)

The Division of Monoclonal Antibodies Kathleen A. Clouse, Ph.D., Director CTGTAC - July 26, 2007.

Carl W. Dieffenbach, Ph.D. Director Division of AIDS, NIAID July 2, 2013 HIV Vaccine and Future Strategies.

State of the Field Exploring 2015’s Top Ten List for the HIV Prevention Research Field Manju Chatani, Stacey Hannah, Mitchell Warren Thursday, January.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC- HIV (vCP1521) Priming With VaxGen gp120 B/E (AIDSVAX® B/E) Boosting in HIV-Uninfected Thai.

What can we learn from diverse spectrum of HIV/SIV infections? Françoise BARRÉ-SINOUSSI Regulation of Retroviral Infections Unit Department of Virology.

Introduction to Regulation

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Special Topics in IND Regulation

REGULATORY ISSUES IN HIV CURE RESEARCH HIV Cure Research Training Curriculum Regulatory Issues Module by: Damon Deming, Ph.D. FDA Division of Antiviral.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.

HIV Vaccine Research & Development

Science at the FDA: Update for the Science Board Jesse L. Goodman, MD, MPH Chief Scientist and Deputy Commissioner for Science and Public Health November.

AIDS Vaccine R&D (post-AIDSVAX®). R&D challenges Products in development Funding AIDS vaccine R&D Access and advocacy.

HIV Vaccine Clinical Trials: In Theory and on the Ground Prof. Omu Anzala Program Director Kenya AIDS Vaccine Initiative (KAVI) Department of Medical Microbiology.

HIV Prevention Trials Network Update Africa Regional Working Group 20 May 2003.

-Challenges for the CSL/Pfizer Animal Ethics Committee John Phelps CSL Biotherapies Meeting Animal Welfare Needs in a Biotherapies Environment.

Prior to exposure Point of transmission After infection Male and female condoms Antiretroviral therapy (mother-to- child) Post exposure prophylaxis (PEP)

1 FDA Regulation of Cell Therapy Celia M.Witten, Ph.D., M.D. Director, Office of Cellular, Tissue, and Gene Therapies Fourth Annual Translational Stem.

RV 144: The Thai Phase III Trial and Development of a Globally-Effective, Multi-Clade HIV Vaccine HIV Vaccine: Quo Vadis AIDS July 2010 Dr. Merlin.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

CONFLICTS OF INTEREST ARE HERE TO STAY: PROTECTING SCIENCE FROM BIAS Susan S. Ellenberg, Ph.D. Center for Biologics Evaluation and Research, FDA Boston,

KATHY MAGRUDER, MPH, PHD DIRECTOR MUSC Office of Research Integrity.

Katharine Kripke, Ph.D. Assistant Director, Vaccine Research Program, Division of AIDS, NIAID AIDS Vaccine 2011 Journalist Training Program September 11,

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Food and Drug Administration

CDC Guidelines for Use of QuantiFERON ® -TB Gold Test Philip LoBue, MD Centers for Disease Control and Prevention Division of Tuberculosis Elimination.

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (Q-Pan H5N1 Vaccine) Manufactured by GlaxoSmithKline Vaccines and Related Biological Products Advisory.

1 Approaches to Demonstrate Effectiveness of Vaccines for Prevention of Group B Meningococcal Disease Introduction Vaccines and Related Biological Products.

Process of FDA New Drug Approval: 1- New Compound with promising preclinical data 2- Sponsor applies to FDA for an IND (Investigational New Drug Application)

FDA’s Critical Path Research Initiative & Intro to the CBER Research Program Kathryn M. Carbone, M.D. Associate Director for Research CBER/FDA.

VRBPAC Topic #2: Clinical Development of Influenza Vaccines for Pre-pandemic Use Joseph G. Toerner, MD, MPH VCTB/DVRPA/OVRR/CBER/FDA February 27, 2007.

1 Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting Detection of Porcine circovirus (PCV) and PCV DNA Sequences in U.S. Licensed.

FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.

FDA Office of Orphan Products Development

IAS Members Meeting July 19th 2011 Achievements and learning over the past 30 years: what do we need next? Françoise BARRÉ-SINOUSSI Regulation of Retroviral.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

HIV-1 Resistance Testing in Drug Development Antiviral Drugs Advisory Committee Meeting November 2-3, 1999.

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

25 Years of HIV Vaccine Research: What have we accomplished? José Esparza MD, PhD Senior Advisor on HIV Vaccines Global Health Program The Search for an.

FDA ADVISORY COMMITTEES Mary A Foulkes, Ph.D. Office of Biostatistics and Epidemiology Center for Biologics Evaluation and Research, FDA FDA/Industry.

The Regulatory Science of Regenerative Medicine Celia M. Witten, Ph.D., M.D., Director Office of Cellular, Tissue and Gene Therapies Center for Biologics.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.

Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

What Is Ethics Review. In Groups More than 33 million people today have HIV and risk contracting AIDS if they do not receive effective inhibitor medications.

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

1 Considerations in the Pre- and Early Pandemic Use of Influenza Vaccine Jesse L. Goodman, MD, MPH Center for Biologics Evaluation and Research, VRBPAC,

CBER: PDUFA IV Meeting Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research 11/14/05.

OVERVIEW OF THE WORKFORCE DEVELOPMENT DOMAIN TASK FORCE APRIL 16, 2015 Joan D. Nagel, M.D., M.P.H. Program Director, Division of Clinical Innovation National.

HVTN 702: A pivotal phase 2b/3 multi-site, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of ALVAC-HIV.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

HIV Vaccine Trials Network

February 11, 2016 Vic Myer, Chief Technology Officer.

Annual Research Day 17 April 2015

Strategy and Policy Cohesion: “The One Health Agenda: will it deliver”

Larry Kessler, Sc.D. Director

Presentation transcript:

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE ALVAC-vCP1521 plus AIDSVAX B/E CRF01_AE (Clade E) -based HIV vaccines Phase 3 Trial in Thailand Sponsor: Office of the Surgeon General, U.S. Army Joseph Toerner, M.D., M.P.H.: FDA, CBER September 23, 2004

PHASE 3 TRIAL IN THAILAND ALVAC vCP1521 prime plus AIDSVAX B/E boost in Thai young adults Differing scientific opinions –For example, Science 2004 vol. 303, 305 Purpose of today’s VRBPAC is to provide an update on the ongoing study for committee members –Decision to allow trial to proceed under US IND –Regulatory challenges

HIV GENETIC DIVERSITY Complicated global diversity –Clades: short sequences of env –New circulating recombinants identified –Recharacterization of clades (Clade E) Potential obstacle HIV vaccine dev. –Superinfection with different clade HIV NEJM 2002;347:731-6 –Broad immunological responses? –How much cross-clade recognition? Much of HIV vaccine development is clade-specific

Vaccine Development, GCP & the Global Challenge Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research (CBER) US FDA Presentation to the 2004 ICDRA Madrid, Spain

HIV Vaccine: Interesting Issues Is US approval possible for an HIV vaccine that incorporates only non-US prevalent clades? What about any approval of a vaccine of limited efficacy (what do we think of 10 v. 20 v. 40 v. 60 v 80% v. 90+ % condoms)? –Behavioral issues, risks to pt and contacts? –High vs. low incidence areas –Actions based on interim analyses? Would the “right” response differ between high/low risk areas?